Course of neurological soft signs in first-episode schizophrenia: Relationship with negative symptoms and cognitive performances

Raymond C. K. Chan¹, Fu-lei Geng¹,², Simon S. Y. Lui¹,²,³, Ya Wang¹, Karen K. Y. Ho³, Karen S. Y. Hung¹, Raquel E. Gur⁴, Ruben C. Gur⁴ & Eric F. C. Cheung³

This prospective study examined the course of neurological soft signs (NSS) in patients with first-episode schizophrenia and its relationship with negative symptoms and cognitive functions. One hundred and forty-five patients with first-episode schizophrenia were recruited, 29 were classified as having prominent negative symptoms. NSS and neuropsychological measures were administered to all patients and 62 healthy controls at baseline. Patients were then followed-up prospectively at six-month intervals for up to a year. Patients with prominent negative symptoms exhibited significantly more motor coordination signs and total NSS than patients without prominent negative symptoms. Despite general improvement in NSS and neuropsychological functions, the prominent negative symptoms group still exhibited poorer motor coordination and higher levels of NSS, as well as poorer working memory than patients without prominent negative symptoms. Two distinct subtypes of first-episode patients could be distinguished by NSS and prominent negative symptoms.

Neurological soft signs (NSS) have been considered among the target features¹ and a potential endophenotype² for schizophrenia. The investigation of NSS has provided important information in the search for the aetiology of the illness³–⁵. A recent meta-analysis showed that NSS is prevalent in patients with first-episode schizophrenia (Cohen's d ranges from 0.68 to 1.53) and chronic schizophrenia (Cohen's d ranges from 0.87 to 1.61), suggesting that the presence of NSS is not confounded by medication side effects and is stable across the different stages of the illness⁶,⁷.

Recent imaging findings have challenged the traditional view that NSS are “non-localizing signs“. A recent meta-analysis⁸ on NSS in schizophrenia suggests that NSS are associated with specific brain structural and functional connectivity changes, mainly involving the cerebello-thalamo-prefrontal network proposed by Andreasen et al.⁹. These regions and neural connections overlap with neural substrates thought to be related to the deficit syndrome of schizophrenia or persistent negative symptoms¹⁰–¹².

¹Neuropsychology and Applied Cognitive Neuroscience Laboratory, Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China. ²University of Chinese Academy of Sciences, Beijing, China. ³Castle Peak Hospital, Hong Kong Special Administration Region, China. ⁴Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, and the Philadelphia Veterans Administration Medical Center, Philadelphia, United States of America. Correspondence and requests for materials should be addressed to R.C. (email: rckchan@psych.ac.cn)
On the other hand, negative symptoms account for much of the long-term morbidity and poor functional outcome of patients with schizophrenia, and treatment of negative symptoms has remained unsatisfactory despite the advent of second-generation antipsychotics. Traditionally there are two approaches for defining negative symptoms in schizophrenia, namely the deficit syndrome and persistent negative symptoms. The prevalence of the deficit syndrome was estimated to be about 15% in first-episode schizophrenia patients and about 25–30% in patients with chronic schizophrenia; whereas the prevalence of persistent negative symptoms varied from 13.2% to 27% in first-episode schizophrenia according to various operational definitions. Schizophrenia patients with the deficit syndrome were found to have impairment in fronto-parietal lobe functions, but not temporal lobe functions such as verbal and visual explicit memory, whereas patients with persistent negative symptoms were found to have abnormalities in both frontal and temporal lobe structures and functions. It has been suggested that the diagnosis of deficit syndrome schizophrenia may be difficult, especially in first-episode patients, even though the deficit/non-deficit categorization appears to be stable.

Patients with deficit syndrome schizophrenia exhibit significantly higher prevalence of deficits in motor coordination, sensory integration and sequencing of complex motor acts signs compared to those without the deficit syndrome. Galderisi et al. further showed that after controlling for the influence of extrapyramidal symptoms, the deficit/non-deficit category was the only clinical variable entering the regression equation on the sequencing of complex motor acts factor, while the negative symptom dimension was associated with the sensory integration factor. Mittal et al. also showed that ultra-high risk individuals exhibit a decrease in fractional anisotropy value in the superior cerebellar peduncle pathway on follow-up after 12 months as compared to healthy controls, although there was no significant difference in the integrity of this pathway at baseline. Taken together, these findings suggest that negative symptoms share common neural substrates with NSS in schizophrenia, especially in the cerebello-thalamo-prefrontal connection. However, Galderisi et al.’s study was limited by a relatively small sample size, patients with a long duration of illness and a cross-sectional design. It is also unclear whether the findings were confounded by chronicity of illness or antipsychotic medication effect.

Despite the substantial number of studies on NSS in the past decades, several issues remain unresolved. One of the most important criteria of a potential endophenotype is its stability across the different stages of the illness. The aforementioned studies were all limited by their cross-sectional design. It is still not clear how the prevalence and nature of NSS evolve and change over the course of illness. This gap in knowledge highlights the need for a prospective longitudinal study. To date, nine studies had specifically examined the prevalence of NSS in patients with first-episode schizophrenia using different NSS scales such as the Neurological Evaluation Scale (NES), the Cambridge Neurological Inventory (CNI), and the Heidelberg Scale. However, most of them were limited by small sample sizes, a short follow-up period or two-time points follow-up, the absence of control comparison and a lack of neurocognitive function assessments (see Table 1).

Another unresolved issue is the relationship between NSS and the symptomatology of schizophrenia. It is especially unclear how NSS associate with negative symptoms throughout the course of the illness. Chen et al. have demonstrated that the association between NSS and negative symptoms was not apparent at least one year after the onset of illness and the association tended to increase up to the third year of the follow-up period. However, they only administered the motor coordination subscale of the Cambridge Neurological Inventory (CNI), which forms only part of the construct of NSS. Prikryl et al. examined patients with and without remission four years after the onset of schizophrenia and found that there was a significant association between NES scores and negative symptoms in patients with first-episode schizophrenia at baseline and four years later. However, their sample was biased towards male participants. It is not clear whether patients with first-episode schizophrenia with prominent negative symptoms would demonstrate a strong association with NSS as compared to patients without prominent negative symptoms, and whether these two subgroups would follow different pathways of evolution over the course of the illness.

The purpose of the present study was to examine the course of NSS in patients with first-episode schizophrenia and its relationship with negative symptoms and cognitive functions. In particular, we attempted to track and compare the changes in NSS between patients with and without prominent negative symptoms within one year of illness onset. We hypothesized that: (1) patients with prominent negative symptoms would exhibit significantly higher prevalence of NSS than patients without prominent negative symptoms; (2) such a pattern would persist within the first year of illness onset at baseline, 6-month, and 12-month intervals; (3) fronto-parietal dysfunctions (working memory) but not fronto-temporal dysfunctions (verbal and visual explicit memory) would be more impaired in patients with prominent negative symptoms than patients without prominent negative symptoms.

Results

Attrition analysis. A total of 36 patients dropped out from the study (attrition rate = 24.8%). Among the patients who dropped out, one committed suicide, two did not return for follow-up, and the remaining 33 patients refused further assessments, even though they continued to attend clinical appointments. A comparison of patients who completed the assessments and those who dropped out showed that there were no significant differences in age (t(143) = 0.17, P = 0.863), education (t(143) = 0.19, P = 0.849), handedness (X^2(1) = 0.69, P = 0.406), and IQ estimates (t(143) = 1.11,
| Studies                  | Patients sample                                                                 | Follow-up Period | Healthy controls | NSS Examination | Main Findings                                                                                       | Limitations                                                                 |
|-------------------------|---------------------------------------------------------------------------------|------------------|------------------|-----------------|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Madsen et al., 1999     | Thirty-four patients with first-episode schizophrenia and 29 patients with other psychotic disorders were recruited. | Only 18 patients were followed up at 5 years later. | Twenty healthy controls were recruited but only 10 being followed up. | SNE              | Patients showed significantly higher prevalence of NSS than healthy controls at baseline assessment. Such a difference increased 5 years later, especially for signs capturing frontal, cortiospinal and tempo-parietal functions. | The SNE is not a standardized and well-validated scale for the evaluation of NSS in schizophrenia population. The patients and controls samples were very small though the follow-up period was 5 years. There was only 2 time-point assessment that could not reflect general longitudinal changes of NSS in patients with schizophrenia. The association between NSS and negative symptoms was not examined. |
| Whitty et al., 2003      | Ninety-seven patients with first-episode schizophrenia and schizophreniform disorders were recruited. | Patients were followed up at 6 months. | Seventy-three healthy controls were recruited and followed up. | NES              | Patients showed significant reduction in NSS at the follow-up assessment suggesting that NSS manifested state-like characteristics that varied with clinical course. | The CNE was not a well-validated scale for NSS assessment. The items included in the CNE consist of both “hard” and “soft” signs. Despite a reasonable large sample for both patients with first-episode schizophrenia and healthy controls, the follow-up period was limited to a 2 time points. The association between NSS and negative symptoms was not examined. |
| Bachmann et al., 2005    | Thirty-nine patients with first-episode schizophrenia spectrum disorders         | Patients were followed up at 14 months | Twenty-two healthy controls were recruited and followed up at 14 months. | Heidelberg Scale | Patients demonstrated significantly higher NSS prevalence than controls at baseline and follow-up. However, the prevalence of NSS remained stable in patients over the two time points. | The items included in the Heidelberg scale consist of both “hard” and “soft” signs. Relative small samples for both patients and controls and the follow-up period was limited to 2 time points. The association between NSS and negative symptoms was not examined. |
| Chen et al., 2005        | One hundred and thirty-eight patients with first-episode schizophrenia, and schizophreniform, and schizoaffective disorder were recruited. | Only 93 patients were followed up at 3 years | Sixty-eight healthy controls were assessed at baseline. | Only motor coordination subscale of the CNE | Patients with medication-naive schizophrenia demonstrated significantly higher prevalence of NSS than healthy controls, and the prevalence of NSS persisted over the 3 years since onset of schizophrenia. The association between NSS and negative symptoms increased gradually from the first year after the initial episode. | The findings were limited to the motor coordination signs. The changes of other signs such as sensory integration and disinhibition were not clear. No additional neurocognitive function assessment was obtained from this study. |
| Prikryl et al., 2007     | Ninety-two male patients with first-episode schizophrenia were recruited.        | Patients were followed up at 1 year. | None | NES              | Patients with remission demonstrated significantly lower NSS prevalence than those without remission. The remitters showed a significant reduction in NSS subscores except sensory integration, whereas the non-remitters reported a significant reduction of the overall NES score. | The findings were limited to male patients and might not be able to generalize to female patients. Relatively small sample for the follow-up of NSS at only 2 time points. The association between NSS and negative symptoms was not examined. |
| Mayoral et al., 2008     | Twenty-four patients with first-episode schizophrenia were recruited.            | Patients were followed up over a 2-year period. | Thirty healthy controls were recruited and followed up 2 years later. | NES              | Patients demonstrated significantly more NSS than controls at baseline assessment, and showed a significant decrease in the sensory integration, others and total NES score over the follow up period, whereas the controls only demonstrated a significant decrease in the total NES score. | Small sample size followed up only at 2 time points. The association between NSS and negative symptoms was not examined. No additional neurocognitive function assessment was obtained from this study. |
| Cuesta et al., 2012      | One hundred patients with medication naive psychotic disorders                  | Only 77 patients were followed at baseline, 1 month and 6 months. | Twenty-eight healthy controls | NES              | Patients receiving atypical antipsychotics showed significant improvement on the total NES score and most NES subscales except for frontal signs. Clinically meaningful changes on the NES score ranged from 25% to 50%. | The study was mainly a drug trial study testing the efficacy of risperidone, olanzapine, mixed antipsychotics or no medication. The sample was mixed with psychotic disorders other than schizophrenia. The relationship between NSS and negative symptoms was not examined. No additional neurocognitive function was obtained from this study. |
| Prikryl et al., 2012     | Sixty-eight male patients with first-episode schizophrenia were recruited.       | Patients were followed up 4 years later. | None | NES              | The patients with remission (57% of the original sample) demonstrated a decrease in the sensory integration and sequencing of complex motor acts. For the patients without remission (43%), they showed increase in the total NES score and other item of the NES. A relationship between NSS and negative symptoms was also found. | The findings were limited to male patients and might not be able to generalize to female patients. Relatively small sample for the follow-up of NSS at only 2 time points. |
| Mayoral et al., 2012     | One hundred first-episode psychosis patients                                     | Fifty-nine patients were followed up 2 years later. | Ninety-eight healthy controls were recruited and only 80 of them were followed up 2 years later. | NES              | Patients showed more NSS than controls both at baseline and the 2-year follow-up. However, the patients demonstrated a significant greater reduction of NSS than the healthy controls at follow-up. No significant differences were demonstrated among different diagnostic groups of schizophrenia, bipolar disorders and other psychoses. | No association of NSS and negative symptoms was evaluated. No additional neurocognitive function assessment was obtained from this study. |

Table 1. Follow-up studies of neurological soft signs in patients with first-episode schizophrenia NES: Neurological Evaluation Scale (Buchanan & Heinrichs, 1989); SNE: Standard Neurological Examination (Madsen et al., 1999); Heidelberg Scale (Schroder et al., 1992).
The two groups did not differ in the proportion of patients with and without prominent negative symptoms (X^2(1) = 0.15, P = 0.701). The two groups also did not differ in antipsychotic medication dosage (t (1280) = 1.957, P = 0.053). However, the dropped-out patients had significantly lower levels of positive symptoms (t (143) = 3.42, P = 0.001), general psychopathology subscale scores (t (143) = 2.19, P = 0.030) and total score on the PANSS (t (143) = 2.20, P = 0.030), suggesting that those who refused to participate were less symptomatic.

**Cross-sectional analysis.** ANOVAs on the IQ estimates indicated that both patients with and without prominent negative symptoms had significantly lower IQ estimates than healthy controls (F (2, 143) = 13.67, P < 0.001), and both patient groups had significantly more male participants than the healthy control group (X^2 (2) = 6.91, P = 0.032) (Table 2). The three groups did not differ in handedness, age, and years of education. An examination of clinical symptoms showed that patients with prominent negative symptoms had, as expected, higher negative symptoms subscale score (t (143) = 15.19, P < 0.001), general psychopathology subscale score (t (143) = 3.28, P = 0.001) and total PANSS score (t (143) = 6.14, P < 0.001). The two groups did not differ in positive symptoms subscale score (t (143) = 1.28, P = 0.203). There were also no significant differences between the patient groups in scores on the Simpson-Angus Scale (t (143) = 1.55, P = 0.132), the Barnes Akathisia Scale (t (143) = 0.04, P = 0.972) and the Abnormal Involuntary Movement Scale (t (143) = 0.78, P = 0.438).

Table 3 summarizes the comparison of NSS and neuropsychological functions between patients with and without prominent negative symptoms, and healthy controls at baseline. An examination of the clinical symptoms showed that patients with prominent negative symptoms had significantly more total and subscale scores of NSS than healthy controls. Moreover, patients with prominent negative symptoms had significantly more motor coordination impairment (t (143) = 2.64, P = 0.009) and total NSS (t (143) = 2.36, P = 0.019) than patients without prominent negative symptoms.

MANCOVA controlling for gender and IQ showed significant differences in neuropsychological performance between patients with and without prominent negative symptoms and healthy controls. Both patient groups performed worse than healthy controls on neuropsychological tests. Independent t tests further indicated that patients with prominent negative symptoms performed worse than patients without negative symptoms in logical memory (t (143) = 2.01, P = 0.047), delay logical memory (t (143) = 2.35, P = 0.020), letter number span correct items (t (143) = 2.64, P = 0.009) and letter number span longest items (t (143) = 2.45, P = 0.015).

**Longitudinal analysis.** The prevalence of prominent negative symptoms in the persistent negative symptoms group was 20.0%, 17.8%, 15.6% at time 1, time 2 and time 3, respectively. Linear growth model for binary data analysis showed that the level of prominent negative symptoms was stable over time (F (1,128) = 1.24, P = 0.27 for slope).

Table 4 shows the trajectories of NSS, clinical symptoms and neuropsychological performances over the three time points. There was a decreasing trend in NSS (F(1,127) = 41.16, P < 0.001), positive symptoms (F(1, 127) = 133.78, P < 0.001), general psychopathological symptoms (F(1, 127) = 113.71, P < 0.001), and WCST perseverative errors (F(1, 127) = 28.81, P < 0.001) in both patient groups. On the other hand, logical memory (F(1, 127) = 36.68, P < 0.001), delayed logical memory (F(1, 127) = 56.61, P < 0.001) and WCST category (F (1, 127) = 16.19, P < 0.001) improved for all patients. Despite this general improvement, patients with prominent negative symptoms still had significantly higher scores indicating greater impairment in motor coordination (F(1,109) = 7.22, P = 0.009) and total NSS scores (F(1, 109) = 4.72, P = 0.034), as well as poorer performance on the LN test (both correct response and longest items) than patients without prominent negative symptoms (Fig. 1). Moreover, the correlation between NSS and negative symptoms increased gradually across the three time points: 0.188, 0.525 and 0.574, respectively. The correlation coefficient between motor coordination subscale score and negative symptoms was 0.196, 0.608 and 0.402, respectively. Similarly, the correlation coefficient between the sensory integration subscale score and negative symptoms for the three time points was 0.082, 0.187 and 0.566, respectively; and the correlation coefficient between the disinhibition subscale score and negative symptoms was 0.101, 0.165 and 0.256 respectively. There was no significant time and group interaction on the entire test in the study.

**Discussion**

The present findings generally confirm results from previous studies examining the prevalence of NSS in first-episode schizophrenia. In particular, our findings show that schizophrenia patients with prominent negative symptoms exhibit significantly higher levels of NSS, mainly in the form of motor coordination signs than patients without prominent negative symptoms. These differences were not confounded by IQ and medication side effects. An examination of the NSS abnormalities indicates that these differences were mainly due to differences in the level of motor coordination signs. Motor coordination signs have been associated with frontal lobe connections such as the cortico-cerebellar-thalamic-cortical...
network\(^9\) and the cerebello-thalamo-prefrontal network\(^{38}\). Our findings highlight the overlap of neural substrates associated with NSS and negative symptoms in schizophrenia\(^{39}\).

For neuropsychological performances, when we compared the two patient groups at baseline, we found that patients with prominent negative symptoms did not perform significantly worse than patients without prominent negative symptoms in most of the fronto-parietal and temporal lobe functions, although these two groups both performed significantly worse than healthy controls. Working memory, a fronto-parietal function measured by the LNS test, was the only significant difference between the two patient groups. The linear growth model analysis indicated that patients with prominent negative symptoms continued to show significant differences in working memory as well as NSS (mainly motor coordination signs) from patients without prominent negative symptoms. Unlike patients with the deficit syndrome who show clear and consistent differential frontal-parietal dysfunctions\(^{11,19,39}\), our findings suggest that patients with prominent negative symptoms might exhibit subtle fronto-parietal dysfunction in the early phase of the illness. The patients in our sample were all suffering from their first-episode of schizophrenia and it is possible that they may have a relatively intact fronto-parietal network than patients in the more chronic stage of the illness. The difference in fronto-parietal lobe functions may only manifest in subtle ways in the early stage of the illness that may not be easily detected using behavioural tests. As the illness progresses, such a dysfunction may become more apparent.

In addition, we also tracked the changes of NSS in patients with schizophrenia since illness onset in the first year. Our data showed distinct trajectories of NSS development over the first year of illness, with patients with prominent negative symptoms exhibiting significantly more NSS than patients without

| Table 2. Demographic and clinical information for patients with schizophrenia with and without prominent negative symptoms, and healthy controls. PANSS: Positive and Negative Syndrome Scale; a, Bonferroni post hoc there is no difference between Prominent and Non-Prominent Negative Symptoms groups (P = 0.065). |
|---------------------------------------------------------------|
| **Patients with Schizophrenia** | **Health controls (N = 62)** | **Comparison** |
|-------------------------------|-----------------------------|----------------|
| **Prominent Negative Symptoms (N = 29)** | **Non-Prominent Negative Symptoms (N = 116)** | |
| Gender (male: female) | 20:9 | 49:67 | 32:30 | \(X^2 = 6.91, \ df = 2, P = 0.032\) |
| Handed (right: left) | 27:2 | 110:6 | 60:2 | \(X^2 = 0.65, \ df = 2, P = 0.724\) |
| Age (year) | 22.34 (4.06) | 21.69 (3.768) | 21.16 (1.89) | \(F = 1.27, \ df = 2, P = 0.283\) |
| Education (year) | 11.72 (1.93) | 11.94 (2.22) | 12.44 (2.18) | \(F = 1.47, \ df = 2, P = 0.233\) |
| IQ estimates a | 96.22 (14.16) | 102.93 (14.39) | 111.52 (13.01) | \(F = 13.67, \ df = 2, P < 0.001\) |
| PANSS | | | |
| Total score | 60.93 (13.91) | 42.16 (14.91) | \(t = 6.14, \ df = 143, P < 0.001\) |
| Negative symptoms | 21.79 (5.22) | 9.48 (3.51) | \(t = 15.19, \ df = 143, P < 0.001\) |
| Positive symptoms | 12.34 (5.44) | 10.98 (5.05) | \(t = 1.28, \ df = 143, P = 0.203\) |
| General psychopathology | 26.79 (6.10) | 21.70 (7.79) | \(t = 3.28, \ df = 143, P < 0.001\) |
| Duration of illness (month) | 2.68 (2.10) | 3.43 (4.37) | \(t = -0.90, \ df = 143, P = 0.372\) |
| Simpson-Angus Scale | 0.88 (1.59) | 0.40 (0.95) | \(t = 1.55, \ df = 143, P = 0.132\) |
| Barns Akathisia Scale | 0.16 (0.45) | 0.16 (0.69) | \(t = 0.04, \ df = 143, P = 0.972\) |
| Abnormal Involuntary Movement Scale | 0.00 (0.02) | 0.07 (0.46) | \(t = -0.78, \ df = 143, P = 0.438\) |
negative symptoms. These findings are consistent with our previous three-year follow-up study of a large sample of first-episode schizophrenia patients. In our previous study, it was found that the prevalence of NSS in patients was stable over the first three years after illness onset, and the association of NSS with negative symptoms progressively increased over this time period. However, only motor coordination of NSS in patients was stable over the first three years after illness onset, and the association of NSS with negative symptoms.

**Table 3. Comparison of neurological soft signs and neuropsychological function performances between patients with schizophrenia and healthy controls at baseline assessment.** CNI: Cambridge Neurological Inventory; LM: Logical Memory; VR: Visual Reproduction; LNS: Letter-Number Span Test; PNS: prominent negative symptoms; NPNS: non-prominent negative symptoms; WCST: Wisconsin Card Sorting Test; a, MANCOVA (Multivariate analysis of covariance) gender and IQ as covariates. Moreover, their findings were limited to male patients.

However, it should be noted that the rate of patients with prominent negative symptoms gradually decreased over time in our study. This gradual decrease in the number of patients with prominent negative symptoms might reflect a “regression to the mean” phenomenon in the measurement. Theoretically, it would be more worthwhile to examine the differences in NSS in patients with and without “persistent” negative symptoms, i.e., those in which negative symptoms persist over six or 12 months. However, the number of patients with persistent negative symptoms in the present first-episode schizophrenia sample was so small that it was not feasible to make any meaningful statistical comparisons and interpretation. Further study recruiting a larger sample of first episode patients with persistent negative symptoms is warranted. Moreover, further clarification of the relationships between negative symptoms and NSS should also be examined in future studies. To the best of our knowledge, the present study is the first to specifically track the evolution of a comprehensive range of NSS (motor coordination, sensory integration, and disinhibition) in patients with first-episode schizophrenia with and without prominent negative symptoms.

This study has several limitations. Firstly, the assessing clinicians were aware of the diagnosis and subject status of the participants when they carried out the assessments. However, neuropsychological examination was conducted separately by research assistants. Moreover, the clinicians who rated the NSS and the research assistants who administered the neuropsychological tests were not informed whether the patients were classified as with or without prominent negative symptoms, nor were they aware of our hypotheses concerning neurological signs in schizophrenia. Secondly, the follow-up period of the developmental trajectories of NSS in these two patient groups was short. Notably, participants who dropped out were less ill than those who remained in the study and had lower scores for positive symptoms. Thirdly, given that the present study did not adopt a population-based study design, the prevalence rate of prominent negative symptoms observed in patients with first-episode schizophrenia should be considered as preliminary in nature. Future study adopting a population-based design should be carried out...
to cross-validate the present findings. Finally, we only used behavioural and clinical measures to capture
the neurological and neuropsychological functions. The differences in fronto-parietal functions between
patients with first-episode schizophrenia with and without prominent negative symptoms may be so
subtle that behavioural measures are not sensitive enough to detect the difference. Moreover, we only
adopted several tests to capture “fronto-parietal” and “fronto-temporal” functions. It should be noted that
these functions may not be fully captured by a single test and not all tests are localized to a particular
brain region. Future study should adopt both structural and functional connectivity measures to capture
any trajectory differences between these two distinct groups of patients.

Notwithstanding these limitations, we demonstrated the presence of both NSS and negative symptoms
in patients with first-episode schizophrenia. The estimated prevalence of prominent negative symptoms
was 20% in our sample and these patients exhibited high prevalence of NSS compared to both patients
without negative symptoms and healthy controls. However, the finding that neuropsychological tests
showed limited difference between these two distinct groups suggests that NSS may be more sensi-
tive in detecting the underlying clinical and neurological manifestations of schizophrenia. Substantial
evidence suggests that clinical features and neurological signs share many similarities, or may even be
equivalent40 in characterizing the different stages of the schizophrenic illness both behaviourally3,7,26 and
morphologically4,22,41. Our findings are consistent with the recent reformulation of schizophrenia as a
neurodevelopmental illness characterized by different stages with specific markers for early detection
and intervention42. The ease of assessment and sensitivity of NSS lends itself as a potentially useful tool
for early detection and identification of schizophrenia. A larger scale longitudinal study for a longer
period of follow-up could further examine the stability and developmental trajectories of NSS as well
as its relationship with prognosis and functional outcome in schizophrenia. Trajectory-based measures
integrating neuropsychological functions and structural and functional imaging data may also facilitate
the understanding of the pathophysiology of the illness.

Method
Subjects. First-episode schizophrenia patients were recruited from the joint research-based
first-episode schizophrenia programme between Castle Peak Hospital of Hong Kong and the Key
Laboratory of Mental Health, Institute of Psychology, the Chinese Academy of Sciences in Beijing43.
The programme aims to investigate a number of potential endophenotypic markers using a family study
approach. In addition to clinical assessment (phenotyping), detailed endophenotype measurements and
DNA collection of both recruited patients and their first-degree relatives are part of the study paradigm.
A number of neurocognitive functions thought to have high translational potential have been chosen
as potential endophenotypes in this study while the inclusion of proteomics in this project may provide
further opportunity to investigate the effect of genotype on psychosis43.
The joint programme is based at Castle Peak Hospital and is the research component of a clinical programme in early intervention service for psychosis in Hong Kong. Since 2001, this clinical programme has been the only publicly-funded psychiatric unit covering inpatient, outpatient, and community services for people with first-episode schizophrenia in a local community (Tuen Mun, Yuen Long, Tin Shui Wai) with a population of around one million, constituting 15% of the entire population in Hong Kong. Because of the scarcity of private psychiatric services in the local community, this clinical programme is expected to cover almost all first-episode patients in the catchment area. Beginning in 2011, 145 patients with first-episode schizophrenia were recruited for the present study. The diagnosis of DSM-IV schizophrenia was ascertained using a “best-estimate” approach based on structured clinical interviews and medical record reviews. Exclusion criteria included (1) a history of substance abuse in the past six months, (2) a history of electroconvulsive therapy in the past six months, (3) a history of neurological disorder, (4) a history of head injury with loss of consciousness for more than 30 minutes, and (5) mental retardation.

At baseline, 123 patients were receiving second-generation antipsychotics (SGA) and eight patients received first-generation antipsychotics (FGA), while 14 patients were un-medicated. Because SGAs were used in the majority of patients, the percentage of maximum BNF (British National Formulary) recommended dose instead of chlorpromazine equivalence was used. The mean dose of antipsychotics was 46.6% of the maximum BNF-recommended dose (SD = 32.1%). Among the 130 patients who were receiving antipsychotics, 32 of them also received anticholinergics (benzhexol, daily dose ranged from 2–8 mg) and two patients received benzodiazepines (lorazepam, daily dose ranged from 1–1.5 mg). Based on medical record review, the mean duration of untreated psychosis and the mean duration of illness were 9.67 months (SD = 16.30 months) and 14.28 months (SD = 17.45 months) respectively. At baseline, among the 145 patients, 74 had received in-patient care.

These patients were then classified into subgroups with and without prominent negative symptoms based on scores on the Positive and Negative Syndrome Scale (PANSS)\(^4\). We adopted the recommended clinical trial operational classification of patients with prominent negative symptoms proposed by

---

**Figure 1.** Trajectory measures showing the significant differences found between patients with and without prominent negative symptoms. (1a) CNI total score on NSS (F(1, 109) = 4.72, P = 0.034) (1b) CNI motor coordination score (F(1, 109) = 7.22, P = 0.009); (1c) LNS total correct score (F(1, 109) = 7.88, P = 0.007); (1d) LNS longest correct item (F(1, 109) = 5.33, P = 0.024).
Rainbowitz et al. These criteria include: (1) Baseline score >4 (moderate) on at least three, or >5 (moderately severe) on at least two negative PANSS subscale items; or (2) PANSS negative subscale score >3 on item 1 (blunted affect) and at least one third of the items with a score >3 and a maximum of two items with a score >3 from the positive subscale. Based on these criteria, a total of 29 patients were classified as having prominent negative symptoms, while 116 patients were classified as without prominent negative symptoms.

Another 62 healthy controls were identified and recruited from the community. They were recruited from youth centres in the neighbouring community and among the supporting staff of the hospital. They were screened by a semi-structured interview conducted by qualified psychiatrists working in the clinical programme. None of them had any family history of psychiatric illness, or suffered from a neurological illness or alcohol/drug dependence. Intellectual functioning was estimated by the short form of the Chinese version of the Wechsler Adult Intelligence Scale-Revised (WAIS-R). This method of prorating has previously been used in estimating intellectual functioning in schizophrenia.

**Neurological soft signs examination.** NSS were assessed by the soft signs subscales of the Cambridge Neurological Inventory (CNI), which has been widely used in patients with schizophrenia in different stages of the illness. The details of the subscales have been described elsewhere. In brief, there were 25 items in the subscales to capture motor coordination (e.g., fist-edge-palm, finger opposition), sensory integration (e.g., left/right orientation, finger agnosia), and disinhibition (e.g., saccade head movement, go/no go response). Each item was rated on a presence (1) or absence (0) scale. Each item score was summed up to a subscale score for motor coordination, sensory integration, disinhibition, and a total score of NSS. A higher score indicates a higher level of NSS. In this study, NSS were assessed by three qualified psychiatrists (SSYL KKYH KSYH) trained with NSS assessment according to the manual of the CNI. Intra-class correlation coefficients between the raters ranged from 0.85 to 0.91.

**Cognitive function assessment.** Fronto-parietal function was assessed by the Letter-Number Span (LNS) test, the modified Wisconsin Card Sorting Test (WCST), and the verbal fluency test. Fronto-temporal function was assessed by the logical memory and the visual reproduction subtests of the Chinese Wechsler Memory Scale.

**Procedures.** Clinical diagnoses and clinical ratings on negative symptoms were conducted by experienced psychiatrists. Independent ratings on NSS and cognitive tests were administered by trained research assistants who were not aware of the clinical rating and classification of patients with and without prominent negative symptoms. Medication side effects were assessed in patients with schizophrenia using the Simpson-Angus Scale, the Barnes Akathisia Scale, and the Abnormal Involuntary Movement Scale. The study was approved by the Ethics Committee of the New Territories West Cluster of the Hospital Authority of Hong Kong and the Institute of Psychology, the Chinese Academy of Sciences in Beijing. Written informed consent was obtained from all participants before the administration of all measures. All patients were assessed at baseline, six months, and 12 months, whereas the healthy controls only received baseline assessment.

**Statistical Methods.** Attrition analysis. In order to compare demographic and neuropsychological variables at baseline between participants who completed all the three assessments and those who dropped out, independent t tests for continuous variables and chi square test for categorical variables were used.

Cross-sectional analysis. Chi square tests were used to compare categorical variables (gender and handedness) between the three groups. ANOVAs were used to compare continuous variables (age, education, and IQ estimates) between the three groups. Independent t tests were used to compare clinical symptoms between patients with and without prominent negative symptoms. MANCOVA was used to compare NSS and neuropsychological function performances with gender and IQ as covariates.

Longitudinal analysis. Linear growth model for a binary outcome was used to examine the stability of prominent negative symptoms. To compare changes of NSS and neuropsychological variables over time between patients with and without prominent negative symptoms, random growth curve models were performed using PROC MIXED in SAS version 9.0 (SAS Institute Inc; Cary, North Carolina). Gender, group (prominent negative and non- prominent negative), time, and group x time interaction were included as fixed effects and intercept and time as random effect. In these models, compound symmetry covariance structure for repeated subject measures and maximum likelihood were set.

**References**

1. M. T. Tsuang & S. V. Faraone. The concept of target features in schizophrenia research. *Acta Psychiatr. Scand. Suppl.* 395, 2–11 (1999).

2. R. C. K. Chan & I. I. Gottesman. Neurological soft signs as candidate endophenotypes for schizophrenia: A shooting star or a Northern star? *Neurosci. Biobehav. Rev.* 32, 957–971 (2008).
3. J. Bombin, C. Arango & R. W. Buchanan. Significance and meaning of neurological signs in schizophrenia: Two decades later. Schizophr. Bull. 31, 962–977 (2005).
4. P. Dazzan & R. M. Murray. Neurological soft signs in first episode psychosis: a systematic review. The British journal of psychiatry. Supplement 43, s50–57 (2002).
5. Heinrichs D. W. B. R. W. The Significance and meaning of neurological signs in schizophrenia. Am. J. Psychiatry 145, 11–18 (1988).
6. R. C. K. Chan et al. Neurological soft signs in individuals with schizotypal personality features. Aust. N. Z. J. Psychiatry 44, 800–804 (2010).
7. R. C. K. Chan, T. Xu, R. W. Heinrichs, Y. Yu & Y. Wang. Neurological Soft Signs in Schizophrenia: A Meta-analysis. Schizophr. Bull. 36, 1089–1104 (2010).
8. Q. Zhao et al. Neurological Soft Signs Are Not “Soft” in Brain Structure and Functional Networks: Evidence From ALE Meta-Analysis. Schizophr. Bull. 40, 626–641 (2014).
9. N. C. Andreasen, S. Paradiso & D. S. O'Leary. "Cognitive dysmetria" as an integrative theory of cerebellar-cortical circuitry? Schizophr. Bull. 24, 203–218 (1998).
10. A. P. Association, Diagnostic and statistical manual of mental disorders-Fourth edition (DSM-IV). (Washington, DC: Author, 1994).
11. G. Bryson, H. A. Whelahan & M. Bell. Memory and executive function impairments in deficit syndrome schizophrenia. Psychiatry Res. 102, 29–37 (2001).
12. K. M. Putnam & P. D. Harvey. Cognitive impairment and enduring negative symptoms: A comparative study of geriatric and nongeriatric schizophrenia patients. Schizophr. Bull. 26, 867–878 (2000).
13. J. Rabinowitz et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophr. Res. 137, 147–150 (2012).
14. R. W. Buchanan et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr. Bull. 36, 71–93 (2010).
15. W. T. Carpenter, D. W. Heinrichs & A. M. I. Wagman. Deficit and nondeficit forms of schizophrenia - The concept. Am. J. Psychiatry 145, 578–583 (1988).
16. R. W. Buchanan. Persistent negative symptoms in schizophrenia: An overview. Schizophr. Bull. 33, 1013–1022 (2007).
17. B. Kirkpatrick, R. W. Buchanan, D. E. Ross & W. T. Carpenter. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 58, 165–171 (2001).
18. C. L. Hovington, M. Bodnar, R. Jouber, A. K. Malla & M. Lepage. Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12, (2012).
19. S. Galderisi et al. Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: A multicenter study. Am. J. Psychiatry 159, 983–990 (2002).
20. D. I. Mayerhoff et al. The deficit state in first-episode schizophrenia. Am. J. Psychiatry 151, 1417–1422 (1994).
21. X. F. Amador & M. H. Conners. Stability of the diagnosis of deficit syndrome in schizophrenia. Am. J. Psychiatry 156, 637–639 (1999).
22. V. A. Mittal et al. Neurological Soft Signs Predict Abnormal Cerebellar-Thalamic Tract Development and Negative Symptoms in Adolescents at High Risk for Psychosis: A Longitudinal Perspective. Schizophr. Bull. (2013).
23. R. W. Buchanan, D. W. Heinrichs. The Neurological Evaluation Scale (NES) - A structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 27, 335–350 (1989).
24. E. Y. H. Chen et al. The Cambridge Neurological Inventory - A clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res. 56, 183–204 (1995).
25. S. Bachmann, C. Bottmer & J. Schroder. Neurological soft signs in schizophrenia. Schizophr. Res. 6, 25–30 (1991).
26. S. Bachmann, C. Bottmer & J. Schroder. Neurological soft signs in first-episode schizophrenia: A follow-up study. Am. J. Psychiatry 162, 2337–2343 (2005).
27. A. L. Madsen, S. Vorstrup, P. Rubin, J. K. Larsen & R. Hemmingsen. Neurological abnormalities in schizophrenia patients: a prospective follow-up study 5 years after first admission. Acta Psychiatr. Scand. 100, 119–125 (1999).
28. M. Mayoral et al. Neurological soft signs in adolescents with first episode psychosis: Two-year followup. Psychiatry Res. 161, 344–348 (2008).
29. R. Prikryl et al. Dynamics of neurological soft signs and its relationship to clinical course in patients with first-episode schizophrenia. Psychiatry Res. 200, 67–72 (2012).
30. M. J. Cuesta, M. S. Campos, E. Garcia-Jalon, A. M. Sanchez-Torres & V. Peralta. Treatment response of neurological soft signs in drug-naive patients with a first psychotic episode. Schizophr. Res. 139, 144–150 (2012).
31. P. Whitty et al. Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. Psychol. Med. 33, 1479–1484 (2003).
32. R. Prikryl, E. Ceskova, T. Kasparek & H. Kucerova. Neurological soft signs and their relationship to 1-year outcome in first-episode schizophrenia. Eur. Psychiatr. 22, 499–504 (2007).
33. E. Y. H. Chen et al. A 3-year prospective study of neurological soft signs in first-episode schizophrenia. Schizophr. Res. 75, 45–54 (2005).
34. M. Mayoral et al. Longitudinal study of neurological soft signs in first-episode early-onset psychosis. Journal of Child Psychology and Psychiatry 53, 323–331 (2012).
35. G. M. Simpson & J. W. Angus. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212, 11–19 (1970).
36. T. R. E. Barnes. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672–676 (1989).
37. W. Gu. ECDEU Amsment Manual for Psychopharmacolg. (US Department of Health, Education, and Welfare, Washington, DC, 1976).
38. S. Mouchet-Mages et al. Correlations of cerebello-thalamo-prefrontal structure and neurological soft signs in patients with first-episode psychosis. Acta Psychiatr. Scand. 123, 451–458 (2011).
39. R. W. Buchanan et al. Neurological impairments in deficit Vs nondeficit forms of schizophrenia. Arch. Gen. Psychiatry 51, 804–811 (1994).
40. R. C. K. Chan et al. Neurological Soft Signs and Their Relationships to Neurocognitive Functions: A Re-Visit with the Structural Equation Modeling Design. Plos One 9, (2013).
41. R.C.K. Chan, X. Di, G. M. McAlonan & Q.-y. Cong. Brain Anatomical Abnormalities in High-Risk Individuals, First-Episode, and Chronic Schizophrenia: An Activation Likelihood Estimation Meta-analysis of Illness Progression. Schizophr. Bull. 37, 177–188 (2011).
42. T. R. Insel. Rethinking schizophrenia. Nature 468, 187–193 (2010).
43. S. S. Y. Lui, P. Sham, R. C. K. Chan & E. F. C. Cheung. A family study of endophenotypes for psychosis within an early intervention programme in Hong Kong: Rationale and preliminary findings. Chin. Sci. Bull. 56, 3394–3397 (2011).
44. S. R. Kay, A. Fiszbein & L. A. Opler. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276 (1987).
45. J. Rabinowitz et al. Negative symptoms in schizophrenia - the remarkable impact of inclusion definitions in clinical trials and their consequences. *Schizophr. Res.* **150**, 334–338 (2013).

46. B. J. Kinon et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. *J. Clin. Psychopharmacol.* **26**, 453–461 (2006).

47. V. L. Stauffer et al. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. *Schizophr. Res.* **134**, 195–201 (2012).

48. H. I. Moller, M. Riedel, N. Muller, W. Fischer & K. Kohnen. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: A randomized double-blind multicenter trial. *Pharmacopsychiatry* **37**, 270–278 (2004).

49. Y. X. Gong. *Manual of Wechsler Adult Intelligence Scale-Chinese version.* (Chinese Map Press, Changsha, 1992).

50. C. R. Blyler, J. M. Gold, V. N. Iannone & R. W. Buchanan. Short form of the ‘WAIS-III for use with patients with schizophrenia. *Schizophr. Res.* **46**, 209–215 (2000).

51. E. W. Chen & R. C. K. Chan. Three subtest short form of the Wechsler Adult Intelligence Scale-III for uses in patients with schizophrenia: A preliminary report. *Hong Kong J Psychiatry* **15**, 39–42 (2005).

52. E. Y. H. Chen & R. C. K. Chan. The Cambridge Neurological Inventory: Clinical, demographic, and ethnic correlates. *Psychiatric Annals* **33**, 202–210 (2003).

53. E. L. S. Chan, E. Y. H. Chen & R. C. K. Chan. Three subtest short form of the Wechsler Adult Intelligence Scale-III for use in patients with schizophrenia: A preliminary report. *Hong Kong J Psychiatry* **15**, 39–42 (2005).

54. R. C. K. Chan & E. Y. H. Chen. Neurological abnormalities in Chinese schizophrenic patients. *Behav. Neurol.* **18**, 171–181 (2007).

55. E. Y. H. Chen & R. C. K. Chan. The Cambridge Neurological Inventory: Clinical, demographic, and ethnic correlates. *Psychiatric Annals* **33**, 202–210 (2003).

56. Y. X. Gong et al. Neurological soft signs discriminate schizophrenia from major depression but not bipolar disorder. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **43**, 72–78 (2013).

57. J. M. Gold, C. Carpenter, C. Randol, P. T. E. Goldberg & D. R. Weinberger. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. *Arch. Gen. Psychiatry* **54**, 159–165 (1997).

58. H. E. Nelson. A modified card sorting task sensitive to frontal lobe defects. *Cortex* **12**, 313–324 (1976).

59. O. Spreen, E. Strauss. *A compendium of Neuropsychological Tests: Administration, Norms, and Commentary.* (Oxford University Press, New York, ed. 2, 1998).

60. Y. X. Gong et al. *Manual of Wechsler Memory Scale-Chinese Version.* (Hunan Medical College Press, Changsha, 1989).

61. D. Wechsler. *Wechsler Memory Scale Manual.* (Psychological Corp, New York, 1987).

**Acknowledgements**

This study was supported by grants from the National Science Fund China Outstanding Investigator Award (81088001), the Beijing Training Project for the Leading Talents in S & T (Z15110000315020) the Knowledge Innovation Project of the Chinese Academy of Sciences (KSCX2-EW-J-8), and the CAS/SAFEA International Partnership Program for Creative Research Teams (Y2CX131003). These funding agents had no role in the study design; collection, analysis, and interpretation of the data; writing of the manuscript; or decision to submit the paper for publication.

**Author Contributions**

R.C.K.C. designed the study, interpreted the findings and wrote up the first draft of the manuscript. F.L.G. and Y.W. analyzed the data. S.S.Y.L., K.K.Y.H. and K.S.Y.H. collected the clinical data. R.E.G., R.C.G. and E.F.C.C. interpreted the findings and made significant contribution to the writing of the manuscript. All authors contributed to and have approved the final text.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Chan, R. C. K. *et al.* Course of neurological soft signs in first-episode schizophrenia: Relationship with negative symptoms and cognitive performances. *Sci. Rep.* **5**, 11053; doi: 10.1038/srep11053 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/